According to the risk stratification of GPGPS, IDH1 and IDH2 were mutant in a majority of the low-risk patients, indicating that these two genes can lead to a lower risk of glioma and GPGPS is qualified to represent the mutant status of IDH. This evidence concerns the gene IDH1 and glioma.